Josh Bilenker’s team at Eli Lilly chops 3 cancer drug programs in pipeline cleanup as their $1.6B IL-10 effort flames out
Eli Lilly cut 3 early and mid-stage cancer drug programs from the pipeline today, 3 weeks after the new oncology team under Josh Bilenker nixed an alliance it had underway in the field with NextCure.
I’m still lining up the drugs with the program, but the targets make for an interesting list.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,500+ biopharma pros reading Endpoints daily — and it's free.